Novo Nordisk latest outlook trim shows “quick momentum loss”
Novo's CEO Maziar Mike Doustdar has adopted an aggressive M&A stance amid weakening company sales.
Business & Regulation
Tidmarsh’s FDA exit marks latest high-profile jockeying at US agencies
Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn
Massive sales for weight loss drugs spur Eli Lilly’s Q3
FDA rejects Regeneron’s pre-filled Eylea HD syringes amid filling facility woes
Novartis Q3: new drugs step up as generics squeeze Entresto
Dupixent stirs Sanofi’s growth as vaccine sales cool
Roche in ongoing discussions with US government over drug pricing, CEO says
